Abbott Laboratories Form 4 insider transactions

Abbott Laboratories Director John G. Stratton reported a transaction involving stock equivalent units on March 31, 2026.

Michael F. Roman, a Director at Abbott Laboratories, reported transactions involving stock equivalent units on March 31, 2026.

Abbott Laboratories Director Patricia Paola Gonzalez reported transactions involving stock equivalent units, reflecting director fees and dividend reinvestment.

Abbott Laboratories Director Robert J. Alpern reported a transaction involving stock equivalent units on March 31, 2026.

Nita Ahuja, a Director at Abbott Laboratories, reported a transaction involving stock equivalent units on March 31, 2026.

Abbott Laboratories Senior Vice President Jacob A. Orville was granted 13,255 restricted common shares as part of the company's 2017 Incentive Stock Program.

Abbott Laboratories Senior Vice President Eric Shroff reported the disposition of 2,093 common shares through tax withholding and an open market sale.

Abbott Laboratories Executive Vice President Christopher J. Scoggins disposed of 4,997 common shares to cover tax liabilities at a price of $116.26 per share.

Abbott Laboratories EVP and Group President Daniel Gesua Sive Salvadori reported the disposition of shares for tax withholding and a subsequent sale.

Abbott Laboratories' Executive Vice President, Louis H. Morrone, reported the sale of company common shares totaling 5,184 units across two transactions.

Abbott Laboratories Executive Vice President Mary K. Moreland reported the disposition of 5,243 common shares through a tax-related transaction and a sale.

Abbott Laboratories' Vice President and Controller, John A. McCoy, Jr., reported the sale of common shares for tax withholding and personal liquidity.

Abbott Laboratories' Chairman and CEO, Robert B. Ford, disposed of 30,308 common shares to cover tax liabilities at a price of $116.26 per share.

Abbott Laboratories EVP and Group President Lisa D. Earnhardt reported the disposal of 8,577 common shares.

Abbott Laboratories' EVP, General Counsel, and Secretary, Elizabeth C. Cushman, reported the sale of common shares to cover tax obligations and an additional sale.

Abbott Laboratories' EVP and CFO, Philip P. Boudreau, disposed of 7,441 common shares to cover tax withholding obligations.

Abbott Laboratories Senior Vice President Eric Shroff received a performance-based restricted stock award of 10,873 shares and an option grant for 44,821 common shares.

Abbott Laboratories' Executive Vice President Christopher J. Scoggins received performance-based restricted stock and stock options.

Abbott Laboratories' EVP and Group President, Daniel Salvadori, received a performance-based restricted stock award of 21,644 shares and 89,226 employee stock options.

Abbott Laboratories Executive Vice President Louis H. Morrone reported the acquisition of performance-based restricted stock and stock options as part of the company's incentive program.

Abbott Laboratories Executive Vice President Mary K. Moreland reported the acquisition of performance-based restricted stock and employee stock options.

Abbott Laboratories' Vice President and Controller, John A. McCoy Jr., reported the acquisition of performance-based restricted stock and employee stock options.

Abbott Laboratories' Chairman and CEO, Robert B. Ford, was granted significant performance-based restricted stock and stock options on February 24, 2026.

Abbott Laboratories' EVP and Group President, Lisa D. Earnhardt, was granted 27,056 performance-based restricted stock units and 111,533 stock options.

Elizabeth C. Cushman, EVP, GC, and Secretary of Abbott Laboratories, was granted performance-based restricted stock and employee stock options.

Abbott Laboratories' EVP and CFO, Philip P. Boudreau, reported the acquisition of performance-based restricted stock and employee stock options.

Abbott Laboratories Director Daniel J. Starks acquired 10,000 common shares in two open market purchases on February 4, 2026.

Abbott Laboratories' Chairman and CEO, Robert B. Ford, acquired 18,800 common shares at a weighted average price of $107.1259.

Abbott Laboratories Director John G. Stratton acquired 313 stock equivalent units, increasing his beneficial ownership to 13,034 units.

Abbott Laboratories Director Michael F. Roman acquired 301 stock equivalent units, increasing his beneficial ownership to 5,882 units.